Emilio Bajetta, Laura Catena, Nicola Fazio, Sara Pusceddu, Pamela Biondani, Giusi Blanco, Sergio Ricci, Michele Aieta, Francesca Pucci, Monica Valente, Nadia Bianco, Chiara Maria Mauri and Francesca Spada Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study Cancer 120
Article first published online: 18 APR 2014 | DOI: 10.1002/cncr.28726
This is the first multicenter phase 2 trial on the activity and safety of first-line therapy with everolimus plus octreotide long-acting repeatable (LAR) in advanced neuroendocrine tumors (NETs) with different histotypes. This study demonstrates the potential activity of the combination everolimus-octreotide LAR to achieve a tumor shrinkage in NETs of all primary sites, independently from presence or absence of carcinoid syndrome.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field